Brief: Enveric Biosciences Advancing Pre-Clinical Development Of EB-003, Pre-Ind Meeting Targeted For Early 2025
25/06/2024 14:08
June 25 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES: ADVANCING PRE-CLINICAL DEVELOPMENT OF
EB-003, PRE-IND MEETING TARGETED FOR EARLY 2025
Source text for Eikon: ID:nBwbDHztta
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003